The Costs of Anonymization: Case Study Using Clinical Data.

URN to cite this document:: urn:nbn:de:bvb:355-epub-765660
DOI to cite this document:: 10.5283/epub.76566

Pilgram, Lisa

; Meurers, Thierry

; Malin, Bradley

; Schaeffner, Elke

; Eckardt, Kai-Uwe

; Prasser, Fabian

; Oefner, Peter J.

; Gronwald, Wolfram

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 14 Apr 2025 05:28

Alternative links to fulltext:DOI Pubmed Pubmed Central

Details

Preview

Export bibliographical data

Abstract

Abstract

Background: Sharing data from clinical studies can accelerate scientific progress, improve transparency, and increase the potential for innovation and collaboration. However, privacy concerns remain a barrier to data sharing. Certain concerns, such as reidentification risk, can be addressed through the application of anonymization algorithms, whereby data are altered so that it is no longer reasonably related to a person. Yet, such alterations have the potential to influence the data set's statistical properties, such that the privacy-utility trade-off must be considered. This has been studied in theory, but evidence based on real-world individual-level clinical data is rare, and anonymization has not broadly been adopted in clinical practice.

Objective: The goal of this study is to contribute to a better understanding of anonymization in the real world by comprehensively evaluating the privacy-utility trade-off of differently anonymized data using data and scientific results from the German Chronic Kidney Disease (GCKD) study.

Methods: The GCKD data set extracted for this study consists of 5217 records and 70 variables. A 2-step procedure was followed to determine which variables constituted reidentification risks. To capture a large portion of the risk-utility space, we decided on risk thresholds ranging from 0.02 to 1. The data were then transformed via generalization and suppression, and the anonymization process was varied using a generic and a use case–specific configuration. To assess the utility of the anonymized GCKD data, general-purpose metrics (ie, data granularity and entropy), as well as use case–specific metrics (ie, reproducibility), were applied. Reproducibility was assessed by measuring the overlap of the 95% CI lengths between anonymized and original results.

Results: Reproducibility measured by 95% CI overlap was higher than utility obtained from general-purpose metrics. For example, granularity varied between 68.2% and 87.6%, and entropy varied between 25.5% and 46.2%, whereas the average 95% CI overlap was above 90% for all risk thresholds applied. A nonoverlapping 95% CI was detected in 6 estimates across all analyses, but the overwhelming majority of estimates exhibited an overlap over 50%. The use case–specific configuration outperformed the generic one in terms of actual utility (ie, reproducibility) at the same level of privacy.

Conclusions: Our results illustrate the challenges that anonymization faces when aiming to support multiple likely and possibly competing uses, while use case–specific anonymization can provide greater utility. This aspect should be taken into account when evaluating the associated costs of anonymized data and attempting to maintain sufficiently high levels of privacy for anonymized data.

Trial Registration: German Clinical Trials Register DRKS00003971; https://drks.de/search/en/trial/DRKS00003971

International Registered Report Identifier (IRRID): RR2-10.1093/ndt/gfr456

Owner only: item control page

Download Statistics

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

nach oben

Details

Preview

Export bibliographical data

Abstract

Abstract

Download Statistics

Downloads

Alternative Statistics (altmetrics)

More literature (via CORE)